ATE244891T1 - Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope - Google Patents

Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope

Info

Publication number
ATE244891T1
ATE244891T1 AT97919749T AT97919749T ATE244891T1 AT E244891 T1 ATE244891 T1 AT E244891T1 AT 97919749 T AT97919749 T AT 97919749T AT 97919749 T AT97919749 T AT 97919749T AT E244891 T1 ATE244891 T1 AT E244891T1
Authority
AT
Austria
Prior art keywords
vaccines
epitopes
cell
present
selection
Prior art date
Application number
AT97919749T
Other languages
English (en)
Inventor
Der Burg Sjoerd Henricus Van
Wybe Martin Kast
Reinaldus Everardus Maria Toes
Rienk Offringa
Cornelius Johannes Mari Melief
Original Assignee
Univ Leiden
Seed Capital Investments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Seed Capital Investments filed Critical Univ Leiden
Application granted granted Critical
Publication of ATE244891T1 publication Critical patent/ATE244891T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97919749T 1996-04-26 1997-04-28 Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope ATE244891T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201145 1996-04-26
EP96203670 1996-12-23
PCT/NL1997/000229 WO1997041440A1 (en) 1996-04-26 1997-04-28 Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes

Publications (1)

Publication Number Publication Date
ATE244891T1 true ATE244891T1 (de) 2003-07-15

Family

ID=26142751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97919749T ATE244891T1 (de) 1996-04-26 1997-04-28 Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope

Country Status (11)

Country Link
US (1) US20070025968A1 (de)
EP (1) EP0900380B1 (de)
JP (1) JP4108126B2 (de)
AT (1) ATE244891T1 (de)
AU (1) AU738649B2 (de)
CA (1) CA2252675A1 (de)
DE (1) DE69723434T2 (de)
DK (1) DK0900380T3 (de)
ES (1) ES2205209T3 (de)
PT (1) PT900380E (de)
WO (1) WO1997041440A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
WO1998058951A1 (en) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
GB9804121D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
AU4078599A (en) * 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
ES2249907T3 (es) * 1998-05-23 2006-04-01 Leiden University Medical Center Anticuerpos de union cd40 y peptidos ctl para el tratamiento de tumores.
JP2002518346A (ja) * 1998-06-17 2002-06-25 エピミューン， インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの用途
EP1105496B1 (de) 1998-08-21 2007-03-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Modifizierte hcv peptid-impfstoffe
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
AU7917200A (en) * 1999-09-30 2001-04-30 Institut Pasteur Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
JP4776131B2 (ja) 1999-11-18 2011-09-21 エピミューン インコーポレイテッド ヘテロクリティックアナログおよび関連方法
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
HK1048068B (en) * 1999-12-28 2008-02-22 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP2278024A1 (de) * 2000-04-28 2011-01-26 Mannkind Corporation Antigener peptide von NY-ESO-1 und deren verwendung als impfstoffe gegen Tumor
EP1363938B1 (de) 2000-08-03 2013-12-11 Johns Hopkins University An endoplasmatischen reticulums chaperonprotein gebundenes antigen als molekulärimpfstoff
BRPI0113400B1 (pt) * 2000-08-21 2018-05-15 Apitope Technology Bristol Método para seleção de peptídeo
EP1619207A3 (de) * 2000-09-01 2006-02-08 Epimmune Inc. HLA-A2.1- Bindungspeptide stammend von HCV und ihre Verwendung
EP1425039A4 (de) 2001-03-23 2005-02-02 Us Gov Health & Human Serv Peptide, die mit dem humanen papillomavirus eine immunreaktion geben
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (de) * 2001-04-06 2007-05-30 Mannkind Corporation Epitop-Sequenzen
US20030124718A1 (en) * 2001-05-18 2003-07-03 Deborah Fuller Vaccine composition
CA2469738A1 (en) 2001-11-07 2003-08-07 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
EP2023143A1 (de) 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogene Streptokokkus-Proteine
US8747855B2 (en) 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
HUE046152T2 (hu) 2011-05-24 2020-02-28 Biontech Rna Pharmaceuticals Gmbh Rák elleni egyedi vakcinák
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CA2892391C (en) 2012-11-28 2023-10-17 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JPWO2019054409A1 (ja) * 2017-09-12 2020-11-12 国立大学法人北海道大学 Ｈｌａタンパク質に相互作用する物質のスクリーニング方法及びスクリーニング用キット
US12247053B2 (en) 2018-10-26 2025-03-11 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) * 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
CA2158281A1 (en) * 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
AU7958994A (en) * 1993-10-05 1995-05-01 Ludwig Institute For Cancer Research Method for provoking immunity by peptides labelled with a photoactivatable group which binds to mhc molecules
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Also Published As

Publication number Publication date
CA2252675A1 (en) 1997-11-06
DE69723434D1 (de) 2003-08-14
ES2205209T3 (es) 2004-05-01
WO1997041440A1 (en) 1997-11-06
EP0900380A1 (de) 1999-03-10
DK0900380T3 (da) 2003-11-03
AU738649B2 (en) 2001-09-20
JP4108126B2 (ja) 2008-06-25
PT900380E (pt) 2003-12-31
JP2000510689A (ja) 2000-08-22
EP0900380B1 (de) 2003-07-09
AU2410697A (en) 1997-11-19
US20070025968A1 (en) 2007-02-01
DE69723434T2 (de) 2004-05-19

Similar Documents

Publication Publication Date Title
ATE244891T1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
Widmann et al. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides
EP0752886B1 (de) Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
Lachmann et al. Raising antibodies by coupling peptides to PPD and immunizing BCG‐sensitized animals
ATE429448T1 (de) Peptidzusammensetzung als immunogen zur allergiebehandlung.
CN111440229B (zh) 新型冠状病毒t细胞表位及其应用
CA2290485A1 (en) Method for the production of non-immunogenic proteins
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
AR020102A1 (es) Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
EP1616876A3 (de) Verfahren zur Identifizierung, Isolierung und Herstellung von Antigenen eines spezifischen Pathogens
GB2255093A (en) Hiv-1 core protein fragments
AU7752487A (en) Immunomodulating compositions and their use
DE69716240D1 (de) Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
DE60229659D1 (de) Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
AU707083B2 (en) Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
Salabert et al. Intradermal injection of an anti‐Langerin‐HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo
Bittner‐Eddy et al. Identification of gingipain‐specific I‐A b‐restricted CD 4+ T cells following mucosal colonization with P orphyromonas gingivalis in C 57 BL/6 mice
EP0753009A1 (de) Malariapeptide
GB8912651D0 (en) Peptide fragments of hiv
ATA171686A (de) Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
Chowdhury et al. Generation of high titer antisera in rabbits by DNA immunization
AU7520398A (en) Test kit for tuberculosis diagnosis or the like
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties